GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

IDRX-42, in development for this rare type of cancer. IDRx received $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.

Through the deal, GSK has nabbed the latter’s lead asset, IDRX-42, a KIT tyrosine kinase inhibitor for gastrointestinal stromal tumor, a rare cancer that develops in the digestive tract. It looks like ...

This gives us access to IDRX-42, a very promising and highly selective KIT tyrosine kinase inhibitor designed to treat gastrointestinal stromal tumors. This adds to our GI cancer portfolio ...

The company is hoping its bet on cancer drugs will pay off, agreeing in January to buy cancer biotech IDRx for as much as US$1.15 billion. The return to oncology is part of a strategic shift as it ...

She pointed to the acquisition of Boston-based cancer-focused biotech IDRx last month as “a good example of what we want to do here.” ...

Hopes were high for a rebound in capital-markets activity this year A few notable Health Care deals along with M&A in the AI-adjacent and reshoring themes occurred in January A pair of ...